The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2542-2548

  Lycke, Nils ^a   Schön, Karin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Anti toxin immunity; B cell; CT; CTA1 DD

Indexed keywords

ADENOSINE DIPHOSPHATE; BACTERIAL PROTEIN; CHOLERA TOXIN; HYBRID PROTEIN; IMMUNOGLOBULIN; VACCINE;

ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; APOPTOSIS; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; CONFERENCE PAPER; CONTAMINATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; GENE FUSION; IMMUNE RESPONSE; MEMORY CELL; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; B-LYMPHOCYTES; CHOLERA TOXIN; IMMUNITY, MUCOSAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; STAPHYLOCOCCAL PROTEIN A;

EID: 0035925563     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00487-4     Document Type: Article

References (47)

1. The B-cell system of human mucosae and exocrine glands
2. The anatomical basis of intestinal immunity
3. Optimism over vaccines administered via mucosal surfaces
4. Lack of local suppression in orally tolerant CD8-deficient mice reveals a critical regulatory role of CD8 + T cells in the normal gut mucosa
5. Antigen presentation by intestinal epithelial cells
6. Cholera toxin enhances antigen presentation
7. Oral vaccination with immune stimulating complexes
8. Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice
9. B cells solicit their own help from T cells
10. Mucosal immunity and tolerance: Relevance to vaccine development
11. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro
12. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response
13. The induction of tolerance by dendritic cells that have captured apoptotic cells
14. Coordinated events during bacteria-induced DC maturation
15. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming
16. The mechanism of cholera toxin adjuvanticity
17. Cholera toxin enhances co-stimulatory activity of macrophages by differentially regulating B7.1 and B7.2 expression
18. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro
19. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression
20. Structure and evolutionary aspects of ADP-ribosylating toxins
21. AB5 toxins
22. Actions of cholera toxin and the prevention and treatment of cholera
23. Cholera toxin and related enterotoxins as potent immune modulators
24. Membrane traffic and the cellular uptake of cholera toxin
25. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against H. felis
26. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems
27. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine
28. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin
29. Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization
30. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
31. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin
32. Genetic detoxification of bacterial toxins: A new approach to vaccine development
33. A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity
34. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity
35. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
36. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
37. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit
38. A novel concept in mucosal adjuvanticity: The CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit
39. Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD
40. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity
41. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2 and germinal center-promoting effects
42. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues
43. Dendritic cell survival and maturation are regulated by different signaling pathways
44. Analysis of adjuvant function by direct visualization of antigen presentation in vivo: Endotoxin promotes accumulation of antigen-bearing dendritic cells in the T cell areas of lymphoid tissue
45. Vaccines for mucosal immunity: Unique delivery systems and immune response analysis for TH1/TH2 and IgE/IgAB cells
46. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
47. Fc receptors